Learning
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
i wonder if blue-tongued goats will produce more milk?
http://www.todayonline.com/articles/137267.asp
Dutch to assess extent of bluetongue sheep virus
Time is GMT + 8 hours
Posted: 19-Aug-2006 01:23 hrs
Dutch vets take blood tests of sheep on a farm near Welsum in March 2001. Eleven farms in the southeast of the Netherlands may have cases of a sheep virus, known as bluetongue, the Dutch agriculture ministry said.
Eleven farms in the southeast of the Netherlands may have cases of a sheep virus, known as bluetongue, the Dutch agriculture ministry said.
.
The disease was first identified Thursday in two sheep at a farm at Kerkrade. A nationwide ban on exports of live cattle, goats and sheep is in place.
.
"Eleven suspected businesses are being examined at the moment," a ministry spokeswoman said.
.
All are in the south of the Limburg province bordering Belgium, where suspected cases are also being examined, she said.
.
The Dutch news agency ANP reported that at one of the 11 farms, with a flock of 1,400 sheep, 12 animals had died in recent days and another six were ill.
.
A security cordon of 150 kilometres (90 miles) has been thrown around the district affected in line with European Union rules.
.
The European Commission will decide Monday on whether to ban the movement of live ruminants from regions surrounding the outbreak, the EU's executive arm said.
.
EU food safety and veterinarian experts would meet on Monday and decide if a response was needed at the EU level to the outbreak of the disease, the commission said in a statement.
.
"So long as we have no further information exports from the Netherlands of all ruminants (cattle, sheep and goats) and live products (embryos, sperm and cells) remains frozen," she said.
.
It is the first time bluetongue disease, found in Greece and Italy, had been reported in northern Europe, the ministry added.
.
Bluetongue is a non-contagious, insect-transmitted, viral disease of sheep, which is not known to affect humans, according to the European Union food safety website.
.
It is characterized by inflammation of the mucous membranes, congestion, swelling and haemmorrhages. Sheep are generally the worst affected, while cattle and goats do not usually show any clinical signs of disease but can carry the virus for a certain period of time and transmit it to sheep.
.
It is treated by restricting the movement of infected animals and through the use of vaccine.
.
Last year the Netherlands exported more than half a million cattle, goats and sheep worth almost 115 million euros (147 million dollars). — AFP
Eleven farms in the southeast of the Netherlands may have cases of a sheep virus, known as bluetongue, the Dutch agriculture ministry said.
.
The disease was first identified Thursday in two sheep at a farm at Kerkrade. A nationwide ban on exports of live cattle, goats and sheep is in place.
.
"Eleven suspected businesses are being examined at the moment," a ministry spokeswoman said.
.
All are in the south of the Limburg province bordering Belgium, where suspected cases are also being examined, she said.
.
The Dutch news agency ANP reported that at one of the 11 farms, with a flock of 1,400 sheep, 12 animals had died in recent days and another six were ill.
.
A security cordon of 150 kilometres (90 miles) has been thrown around the district affected in line with European Union rules.
.
The European Commission will decide Monday on whether to ban the movement of live ruminants from regions surrounding the outbreak, the EU's executive arm said.
.
EU food safety and veterinarian experts would meet on Monday and decide if a response was needed at the EU level to the outbreak of the disease, the commission said in a statement.
.
"So long as we have no further information exports from the Netherlands of all ruminants (cattle, sheep and goats) and live products (embryos, sperm and cells) remains frozen," she said.
.
It is the first time bluetongue disease, found in Greece and Italy, had been reported in northern Europe, the ministry added.
.
Bluetongue is a non-contagious, insect-transmitted, viral disease of sheep, which is not known to affect humans, according to the European Union food safety website.
.
It is characterized by inflammation of the mucous membranes, congestion, swelling and haemmorrhages. Sheep are generally the worst affected, while cattle and goats do not usually show any clinical signs of disease but can carry the virus for a certain period of time and transmit it to sheep.
.
It is treated by restricting the movement of infected animals and through the use of vaccine.
.
Last year the Netherlands exported more than half a million cattle, goats and sheep worth almost 115 million euros (147 million dollars). — AFP Eleven farms in the southeast of the Netherlands may have cases of a sheep virus, known as bluetongue, the Dutch agriculture ministry said.
.
The disease was first identified Thursday in two sheep at a farm at Kerkrade. A nationwide ban on exports of live cattle, goats and sheep is in place.
.
"Eleven suspected businesses are being examined at the moment," a ministry spokeswoman said.
.
All are in the south of the Limburg province bordering Belgium, where suspected cases are also being examined, she said.
.
The Dutch news agency ANP reported that at one of the 11 farms, with a flock of 1,400 sheep, 12 animals had died in recent days and another six were ill.
.
A security cordon of 150 kilometres (90 miles) has been thrown around the district affected in line with European Union rules.
.
The European Commission will decide Monday on whether to ban the movement of live ruminants from regions surrounding the outbreak, the EU's executive arm said.
.
EU food safety and veterinarian experts would meet on Monday and decide if a response was needed at the EU level to the outbreak of the disease, the commission said in a statement.
.
"So long as we have no further information exports from the Netherlands of all ruminants (cattle, sheep and goats) and live products (embryos, sperm and cells) remains frozen," she said.
.
It is the first time bluetongue disease, found in Greece and Italy, had been reported in northern Europe, the ministry added.
.
Bluetongue is a non-contagious, insect-transmitted, viral disease of sheep, which is not known to affect humans, according to the European Union food safety website.
.
It is characterized by inflammation of the mucous membranes, congestion, swelling and haemmorrhages. Sheep are generally the worst affected, while cattle and goats do not usually show any clinical signs of disease but can carry the virus for a certain period of time and transmit it to sheep.
.
It is treated by restricting the movement of infected animals and through the use of vaccine.
.
Last year the Netherlands exported more than half a million cattle, goats and sheep worth almost 115 million euros (147 million dollars). — AFP Eleven farms in the southeast of the Netherlands may have cases of a sheep virus, known as bluetongue, the Dutch agriculture ministry said.
.
The disease was first identified Thursday in two sheep at a farm at Kerkrade. A nationwide ban on exports of live cattle, goats and sheep is in place.
.
"Eleven suspected businesses are being examined at the moment," a ministry spokeswoman said.
.
All are in the south of the Limburg province bordering Belgium, where suspected cases are also being examined, she said.
.
The Dutch news agency ANP reported that at one of the 11 farms, with a flock of 1,400 sheep, 12 animals had died in recent days and another six were ill.
.
A security cordon of 150 kilometres (90 miles) has been thrown around the district affected in line with European Union rules.
.
The European Commission will decide Monday on whether to ban the movement of live ruminants from regions surrounding the outbreak, the EU's executive arm said.
.
EU food safety and veterinarian experts would meet on Monday and decide if a response was needed at the EU level to the outbreak of the disease, the commission said in a statement.
.
"So long as we have no further information exports from the Netherlands of all ruminants (cattle, sheep and goats) and live products (embryos, sperm and cells) remains frozen," she said.
.
It is the first time bluetongue disease, found in Greece and Italy, had been reported in northern Europe, the ministry added.
.
Bluetongue is a non-contagious, insect-transmitted, viral disease of sheep, which is not known to affect humans, according to the European Union food safety website.
.
It is characterized by inflammation of the mucous membranes, congestion, swelling and haemmorrhages. Sheep are generally the worst affected, while cattle and goats do not usually show any clinical signs of disease but can carry the virus for a certain period of time and transmit it to sheep.
.
It is treated by restricting the movement of infected animals and through the use of vaccine.
.
Last year the Netherlands exported more than half a million cattle, goats and sheep worth almost 115 million euros (147 million dollars). — AFP
thanks for pointing that out. i thought that those boards might be of some value in the future and drew a conclussion before i checked the companies news releases for that time frame. it was too easy and good to be true.
check out this post and the date on it and then check out IDIX CHART and where the stock was trading on that day, it looks like the news started to get out right about that time frame. knowledge is power, it just has to be found and acted upon in time.
Janice D. Says:
March 23rd, 2006 at 5:37 pm
Okay, they are reducing the dosage in the trials. Evidently, even though the viral load response has been nothing short of extraordinary for those on 800 mg. of NM283, they feel confident that a lower dose (400 or even 200 mg) will be sufficient to do the job, and with a much lower rate of gastro-intestinal problems. Interestingly, the rate of of GI problems was not huge, and most people that had them only experienced them for a short period of time. I guess that’s what a IIb trial is all about: find the optimal dosage with the least side effects. Otherwise, the drug appears very safe, and also incredibly effective. We’ll beat this virus with NM283, mark my words!
>>Medium risk in the treatment-naïve setting, and high risk in the treatment-refractory setting, IMO. The reason for this disparity is that the 200mg once-daily dose seems to be sufficient to reduce viral load in the treatment-naïve setting, but it is not enough to reduce viral load in the treatment-refractory setting. Doses higher than 200mg/day may be problematic due to GI side effects. Regards, Dew<<
Dew, are GI side affect so unbearable that a treatment refractory patient will be willing to allow the hcv virus to continue its destructive course because of it?
my mother who has hcv would not be deterred from taking nm simply because of some simple GI side affects. she has endured the affects of other hcv treatments and would gladly put up with more if it allowed her liver to keep on functioning.
i have seen how willing she is to take anything and put up with side affects as long as the virus is contained, and although i agree that the simpler the drug is to take the more likely a patient would be to follow the recommended dosing instructions, this is another issue that would not keep her from stopping to take the drug, whether it is once a day, or three times a day, heck she's shoot it into herself if need be.
how difficult would you say these GI side affects be to manage?
your high risk and medium risk assessment seem to say that you do not believe novartis nor idenix might be able to find a way around the GI affects and thus limiting the usage for their hcv candidate (nm-283) to the lower dose range.
what are the chances the vrtx hcv candidate may run into "issues" given how far down the road they are in their trial.
what are the chances the idenix hcv candidate may run into "issues" given how far down the road they are in their trial.
which drug may not be able to fully prove itself to even make it to market once all trials are completed.
might one of these drugs prove itself incapable of being tolerated.
the nm issue on the radar seems to be whether the dosing will be higher or lower dosages.
the vx-950 issue on the radar screen is not as clear to me because i am not entirely sure how far they have studied their drug in comparable trials to nm.
nobody really knows whether either of these drugs will ever make it to mkt simply because noone is prescient.
just bought some on scottrade...got filled right quick, go goats.
Dew, in light of the fact that idenix will be presenting today and tomorrow at two investor conferences i have a query for you.
who participates (is invited) to these events?
is it potential investors ?
or is it for the analysts from the selected investment house?
is there a website where an investor can get information on scripts of the different drugs in the marketplace, a place that serves as a clearinghouse on the varied drugs and their adoption cycle in the marketplace?
tia
>>Their error is assuming the manipulation lasts longer than it does, not that the manipulation didn't exist in the first place. That said, I too find the constant blather about manipulation tiresome. It happens/happened. Get over it.<<
a very real concern is that trading ought to be more mechanical and manipulation should not occur at all at the price/bid...i will concede that manipulation via company misrepresentation will more than likely be with us always but the trading process ought to be more transparent...
the bar needs to be raised and the punishment should dissuade the next man from thinking of participating, in my opinion monetary fines are not strong enough...shutting the doors of any house found participating and distributing their assets to some charity would suit me just fine...maybe i feel that way because i feel strongly about being cheated out my hard earned capital.
fuzeon sales seem to be picking up...
their one year estimate is 140 million to 150.... and they are at 55 million at the end of the first qtr, the first qtr according to their execs has been the weakest and was expected to be the weakest this year also.
http://biz.yahoo.com/ap/060510/earns_trimeris.html?.v=1
Trimeris Posts Narrower 1Q Loss
Wednesday May 10, 4:34 pm ET
Trimeris Posts Narrower 1st-Quarter Loss on Strong Sales of Fuzeon HIV Drug
MORRISVILLE, N.C. (AP) -- Biotech company Trimeris Inc. said Wednesday its first-quarter loss narrowed considerably as its revenue rose thanks to strong sales of Fuzeon, an HIV drug.
The company posted a loss of $428,000, or 2 cents per share, compared with a loss of $5.5 million, or 25 cents per share, during the same period a year ago. Excluding stock options costs, the company earned $643,000, or 3 cents per share.
Revenue and collaboration income was $7.4 million, compared with last year's $2.2 million.
Analysts, on average, were expecting a loss of 6 cents per share and revenue of $5.1 million, according to a poll by Thomson Financial.
Sales of Fuzeon are recorded by the company's collaborative partner, F. Hoffmann-La Roche Ltd., the U.S. prescription drugs unit of Swiss pharmaceutical company Roche Holding Ltd. The drug's worldwide sales were up 31 percent, to $55.4 million compared with the year-ago period.
Trimeris said it still expects to be profitable over the full year.
Fuzeon works by stopping HIV from fusing with human cells where anti-retroviral treatments have failed.
Shares rose 44 cents, or 4 percent, to $11.70 in after-hours electronic trading, having earlier closed at $11.26 on the Nasdaq.
better than expected.....
Excluding employee stock option expense, its earned $643,000,
or 3 cents per share, in the latest quarter.
--For the latest quarter, eight analysts on average had
expected the company to lose 7 cents a share, excluding any
exceptional items, according to Reuters Estimates.
(Reporting by Tuhin Kar in Bangalore)
trimeris at morgan stanley conference today...
05/05/06 8:45 a.m. ET
Trimeris, Inc. at Morgan Stanley Global Healthcare Unplugged Conference
Trimeris, Inc. Earnings Conference Call (Q1 2006)
Scheduled to start Wed, May 10, 2006, 5:00 pm Eastern
Short Interest
3,413,915.000
there a lot of shares to cover and very little availability.
i want to see a covering rally to say the least.
for the rpbif.ob fans on the board...thanks dr bio.
whats up with the five letter name with the ob at the end?
Response Biomedical Reports 2005 Financial Results
Vancouver, British Columbia, May 1, 2006 – Response Biomedical Corporation (TSX–V: RBM, OTCBB: RPBIF) today reported financial results for the year ended December 31, 2005. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP). Select operational and financial results are outlined below and should be read in conjunction with the Company’s audited consolidated financial statements and related MD&A which can be found at www.responsebio.com, SEDAR (Canada) www.sedar.com, or EDGAR (US) www.sec.gov/edgar/searchedgar/webusers.htm.
In announcing the results, President and Chief Executive Officer Bill Radvak said, “2005 was a year in which we significantly expanded our opportunities to leverage the RAMP platform, increased traction in key markets and furthered our strategic partnerships. In early 2006, we significantly improved the Company’s financial position by closing a $12 million private placement. We are positioned to execute on our business strategy for RAMP in 2006, including exploiting opportunities we see in rapid clinical cardiovascular and infectious disease testing.”
Summary Fiscal 2005 Results
Total revenues for the year ended December 31, 2005 were $3.49 million compared to $2.68 million in 2004, an increase of 30%. Revenue from product sales for the year ended December 31, 2005 were $3.1 million compared to $2.1 million in 2004, an increase of 45% largely due to an increase in biodefense product sales of 87% to $1.64 million compared to $880,000 in 2004. The increase in biodefense product sales was primarily due to a growing customer base and growing acceptance of the Company’s products following completion in November 2004 of an 18–month study performed by AOAC International and funded by the U.S. Department of Homeland Security and the U.S. Department of Defense in which the RAMP Anthrax Test was the only handheld anthrax test to receive AOAC certification. Clinical cardiac product sales for the year ended December 31, 2005 increased 46% to $740,000 compared to $506,000 in 2004 due to timing of shipments to the Company’s distributor in China. Sales of the Company’s West Nile Virus products for the year ended December 31, 2005 decreased 5% to $707,000 compared to $741,000 in 2004 due to weather patterns that were less conducive to the spread of the disease. Revenue from contract service fees and collaborative research arrangements for the year ended December 31, 2005 were $401,000 compared to $550,000 in 2004, a decrease of 27%. This decrease was primarily due to the timing of the performance of services required to recognize service revenue from the Company’s collaborations with 3M Co., Shionogi & Co., Ltd. and General Dynamics Canada Ltd.
Gross margin for the year ended December 31, 2005 increased to 53% compared to 48% in 2004 due to improved efficiencies offset partially by a change in product mix.
For the year, the Company reported a loss of $8.4 million ($0.12 per share) compared to a loss of $4.9 million ($0.08 per share) in 2004. The increase in loss is primarily due to increased marketing and business development expenses incurred to penetrate the U.S. point–of–care cardiovascular market, increased research and development expenditures for new research and development projects, and license fees to Roche Diagnostics for rights to develop a RAMP NT–proBNP test.
The Company’s working capital deficiency as of December 31, 2005 was $2.9 million, a decrease of $6.0 million from working capital of $3.1 million as of December 31, 2004 principally attributable to cash used in operating activities during the year of $5.5 million, an increase in accounts payable and accrued liabilities of $1.5 million as the Company worked to complete financings that were closed subsequent to year–end, a decrease in inventories of $330,000 to conserve cash, and purchases of property plant and equipment of $535,000 made primarily to increased test manufacturing capacity. This was offset by gross proceeds received from the issuance of $1.56 million in convertible debentures less deferred financing and share issue costs, the use of its line of credit in the amount of $1.1 million, and the exercise of stock options for $141,000.
another periodical with the fuzeon affect...i believe the fuzeon affect is being recognized as seen in the increasing sales of fuzeon...once bioejector 2000 is approved more will be accepting of this drug.
http://www.medicalnewstoday.com/medicalnews.php?newsid=35252
there is an internet address towards the middle of this page that leads to the guidelines of the dhhs with regards efuzeon
DHHS guidelines - clear recommendations for FUZEON use with
boosted PIs
The importance of FUZEON in the management of HIV has been
recognised by the US Department of Health and Human Services (DHHS).
Their newly updated HIV/AIDS treatment guidelines support the use of
FUZEON with an active boosted PI for the management of treatment
experienced patients. The guidelines state that adding a drug with
activity against drug-resistant virus (e.g. a boosted PI such as
TMC114/r) and a drug with a new mechanism of action (e.g. an HIV
entry inhibitor such as FUZEON) can provide significant
antiretroviral activity.
These data come at a pivotal time as Tibotec has launched this
month an international expanded access programme for TMC114/r. This
will enable patients that are rapidly running out of new treatment
options early access to this investigational agent, which has been
seen to be highly promising when used in combination with FUZEON.
The updated DHHS guidelines (October 6, 2005) are available at
online: http://aidsinfo.nih.gov/guidelines/. <<<<<<<<<<<<<<<<<<<<<
TMC114 is an investigational product
Growing Body of Evidence, RESIST 1&2 / POWER 1&2 / TORO 1&2 -
Collectively the data from all six studies, in over 2,500 patients,
establish a new paradigm in the management of triple
class-experienced patients.
continued from previous post...
This adds to the growing body of evidence for the powerful "FUZEON
effect" which has been seen across the RESIST 1 & 2, POWER 1 & 2 and
TORO 1 & 2 studies, where adding FUZEON was seen to almost double the
number of patients reaching undetectable, when combined with one of
the latest boosted PIs such as lopinavir/r, tipranavir/r or TMC
114/r.
Doctors underestimate significant "FUZEON effect"
Surprisingly, of the 560 doctors surveyed onsite this week at the
IAS conference, three quarters (75%) underestimated the "FUZEON
effect" seen in both RESIST(2) and POWER(3) studies.
Latest data adds to growing Body of Evidence - Latest Boosted
Protease Inhibitors (lopinavir/r, tipranavir/r and TMC 114/r) all
work best in combination with FUZEON
RESIST Phase III tipranavir trials
- Over 24 weeks, almost double the proportion of patients who
received FUZEON plus tipranavir/r showed a 90% drop in viral load
compared with patients not receiving FUZEON
POWER Phase II TMC114 dosing trials
- Over 24 weeks in the combined TMC114 trials, almost double the
proportion of patients who received FUZEON plus TMC114/r achieved a
viral load below 50 copies/ml compared with patients not receiving
FUZEON
- A remarkable 67% of the patients receiving FUZEON plus TMC114/r
reached an undetectable viral load
TORO Phase III FUZEON trials
- Over 24 weeks, double the proportion of patients who received
FUZEON plus lopinavir/r achieved an undetectable viral load (<50
copies/ml) compared with patients not receiving FUZEON
Collectively the data from all six studies, in over 2,500
patients, establish a new paradigm in the management of triple
class-experienced patients.
Why FUZEON is effective in face of HIV resistance
FUZEON is still the first and only anti-retroviral drug to work
outside the human immune cell (CD4), blocking the HIV virus from
entering. All other currently available HIV drugs fight the HIV virus
once it has entered the cell. FUZEON's unique mode of action means
that FUZEON has no cross-resistance with currently available drugs
and that it is an effective treatment, in combination with other
anti-HIV drugs, for patients facing resistance.
New combination improves quality of life
Spike, a 48 year old person living with HIV from London, whose
blood levels of HIV reached undetectable within six months of taking
FUZEON and boosted tipranavir and has remained undetectable ever
since, explains "This new combination of treatments has really
improved my quality of life. Getting back to undetectable and seeing
my CD4 count increase from 20 to 268 has changed my outlook on life.
I believe I can plan for the future, which I didn't even consider
doing before starting this regimen. I have much more energy now than
I had before, which is exhilarating since I have been held back for
so long." Spike has been living with HIV since it was detected in his
body in 1986 and works as a freelance designer and night-club
promoter.
The use of FUZEON is continuing to grow, despite initial
reluctance from patients and physicians to using an injection, and
more patients are now successfully starting and remaining on
treatment. Roche continues to roll out educational initiatives to
support patients and physicians with the administration and use of
FUZEON.
References:
(1) Grinsztejn B et al. IAS 2005 Abstract WePe 16.7B07
(2) Cooper D et al. CROI 2005 Abstract 560
(3) Katlama C et al. CROI 2005 Abstract 164LB
ots Originaltext: Roche Pharmaceuticals
Im Interne
here is a little reading on the so called fuzeon affect that the execs at trimeris were boasting about at the jan 31 fuzeon sales update...
27.07.2005 - 12:39 Uhr
Rio De Janeiro, Brazil (ots/PRNewswire) -
- Giving Patients Facing HIV Resistance Their Best Chance to
Achieve Undetectable Viral Loads
Data presented at IAS build a compelling case for FUZEON
(enfuvirtide, formerly known as T-20) to be combined with the newest
drugs to give patients facing resistance their best chance of
achieving undetectable viral load - the optimal treatment goal for
all people living with HIV.
"Undetectable viral load should be the ultimate treatment goal for
all triple-class experienced patients. FUZEON combined with the
latest drugs now makes this much more achievable," explained Dr Mike
Youle the Royal Free Hospital, London. "We are seeing a consistent
FUZEON effect with these new drugs and I believe these data must
change the way we manage triple class experienced patients facing HIV
resistance and failing to reach undetectable viral load."
Studies presented this week show that when FUZEON was given in
combination with the novel HIV medication, tipranavir, an impressive
70% of FUZEON naïve patients achieved a ten-fold reduction in their
viral load and furthermore they also had double the increase in
immune cell count(1), compared to patients receiving tipranavir/r
without FUZEON.
Dew this is for the idix followers from bloomberg news..
Gilead's Hepsera Doesn't Always Work as Hepatitis B Backstop
April 26, 2006 17:58 EDT -- Gilead Sciences Inc.'s Hepsera for hepatitis B isn't universally effective for patients who develop resistance to other treatments, according to a study that says testing and better drugs are needed.
Dew, congrats on your success on those shorts.
can you post an opinion on trimeris fuzeon drug for hiv infected individuals....sales of the drug are starting to show up on the radar screen and i am curious as to what you may think of it....on another note my mother has had hcv virus for over fifteen years now and is still going strong, recently her doctor took her off any medication due to some medical reasoning associated with her age and some other jargon..the bottom line for us is that she will be unmedicated and we need to find another glimer of hope ....the only thing i have been able to come up with is colloidal silver.....she will be getting her viral count checked and we will probably put her on the silver and check after a few months whether the viral count has been diminished or not.....my mother is seventy two and other than the liver she is very healthy and strong.
when there are no medications available from the pharmas one must do what one must do...
fuzeon sales are starting to show an uptick......
>> trimeris today announced worldwide net sales of FUZEON for the first quarter were $55.4 million, up 31 percent from $42.5 million for the first quarter of 2005. Net sales of FUZEON in the U.S. and Canada for the first quarter of 2006 were $27.4 million, up 17 percent from $23.3 million in the first quarter of 2005. Net sales of FUZEON outside the U.S. and Canada for the first quarter were $28.0 million, up 47 percent from $19.1 million for the first quarter of 2005. <<
Hi mskatie, what do you think about this release scheduled for the 25th....would they be reporting on this if the news wasnt going to be good on it?
Trimeris to Release First Quarter 2006 FUZEON Sales Results on Tuesday April 25, 2006
Friday April 21, 4:05 pm ET
MORRISVILLE, N.C.--(BUSINESS WIRE)--April 21, 2006--Trimeris, Inc. (NASDAQ: TRMS - News) today announced that it will release FUZEON sales results for the first quarter of 2006 on Tuesday, April 25, 2006, at 4:00 P.M. Eastern Time. Trimeris' announcement will be followed by a conference call at 4:15 P.M., led by Steven D. Skolsky, Chief Executive Officer, and other members of senior management.
i cant imagine where all that info could be compiled.
i will say a because the other are there to put in perspective the size of the drub market.
A
Hi Dew, can you tell me whether the technology that ntmd uses is similar to the one from france that made that deal announced today.
LONDON, March 2 (Reuters) - French biotechnology company NicOx <NCOX.PA> has signed an eye treatment agreement with Pfizer Inc. < PFE > worth up to 323 million euros ($385.8 million), sending its stock soaring on Thursday.
The deal is the largest for the small firm, which specialises in developing nitric oxide-releasing versions of drugs that offer therapeutic advantages over traditional formulations.
I hope your father continues to improve.
i had mentioned on this board about my girlfriends father who had been diagnosed with pancreatic canx..well he is undergoing an operation this afternoon which will inject some plastic type cement into the area around the vertebraes which have been damaged by the spread of the canx into the bones....this canx is the most unbelievable destroyer that i have ever seen.
thanks to the members of this board for all the panc canx info i have been able to pass onto my girlfriends family.
im looking for this stock to move similarly to nvax.....from well below a buck to where it is today....check out nvax to see into the future......i sure hope these guys really find something suitable for hn51.
trade em if you have got em
Hi dew, great to hear that your father has come out of his surgery and is on the road to recovery. My girlfriends father was recently diagnosed with pancreatic cancer and will be starting chemotherapy with tarceva at the end of this week and we all have been amazed to discover just how little there is out there to treat this monstrocity of a disease.
Dew, your father will be in my prayers also. my father who is 82 had a hip fracture last year and thus far has recovered well.
randy,
i panicked at 1.10 when i wanted to buy and just couldnt do it. sometimes opportunity knocks and we just dont answer cause we suspect it may be the boogie man.
i wonder if everytime a bell rings if an angel really gets its wings.
ill buy back after i do some research tonight.
i am a totally rookie at biotechs and was stopped out cold....and now im frozen like a deer in the headlights....ive never seen this kind of stock action for lack of a better description....ever.
that chart needs a lot of work......or the wizard of oz could just put it back together again like magic.
ohmmmmmmmmmm
ohmmmmmmmmmm
ohmmmmmmmmmm
im in a trance
volume at 2ml and its still below the 200 ave.....1.36 now
i started buying this stock when it was sub one dollar....the long term chart says there could be a lot of resistance above two dollars....do you see it any differently gateway? do you have any goal posts set up for how you might see it trading on the way up?
it would be nice to see more people come over to this board...
with regards to the stem juice from pineapple i have heard of similar results using the center of the banana stem where the bananas grow on in the same fashion and is supposed to diminish or reduce tumors.